DOR BioPharma, Inc., based in Miami, FL, is a biopharmaceutical company
addressing the life-threatening side effects of cancer and cancer
treatments, serious gastrointestinal diseases and disorders, and
biodefense vaccines. Its lead product orBec®
is a potent, locally acting corticosteroid being developed for the
treatment of gastrointestinal graft-versus-host disease (GI GVHD), a
common serious side effect of bone marrow and stem cell transplantation
for cancer. On September, 22, 2006, DOR announced the filing of a New
Drug Application (“NDA”)
with the FDA for the treatment of GI GVHD using orBec®.
DOR’s biodefense vaccine programs are focused
on two potentially lethal biological toxins, ricin and botulinum.
About Wall Street Advisor
Wall Street Advisor is an independent equity research publishing and
distribution company with AIMR-qualified professional analysts. Their
forecasts, opinions and recommendations are their own and therefore
should not be attributed to DOR BioPharma, Inc. Please see full report
for important disclaimers. Full details of the company's policies and
guidelines are posted on the website at http://www.wallstreetadvisor.com.
